NCT05400122 2025-11-12
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Case Comprehensive Cancer Center
Phase 1 Suspended
Clinical Trials
3 trialsNCT04893252 2022-11-30
Vactosertib and Durvalumab in Gastric Cancer
National Cancer Center, Korea
Phase 2 Unknown
NCT04656002 2022-06-15
As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers
Samsung Medical Center
Phase 2 Unknown